HomeAI · summaries
Storia in 5 fonti
Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children - Vertex Pharmaceuticals (N
FDA expands Vertex Casgevy label to patients aged 2 and older, making about 5,500 more U.S. children eligible for the therapy.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease…
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
- ·
healio.com
FDA expands Casgevy approval to children 2 years and older with sickle cell disease
